Next-generation sequencing (NGS), with its increased sensitivity, might pave the way to a more accurate MRD monitoring of FLT3-ITD in AML patients.24–26 In this regard, Zuffa et al.27 developed an amplicon based-ultra deep sequencing (UDS ) approach for FLT3 mutational screening that revealed the presence of small ITD+ clones in 5 of 256 normal karyotypes (CN-) AML patients, who were FLT3 wild-type at presentation, but tested ITD+ at relapse or disease progression. Here, FLT3 is linked to acute myeloid leukemia.